Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncologic Confirmatory Trial Accrual Is Part Of FDA-EMEA Agreement

Executive Summary

FDA will share information with the European Medicines Agency to ensure that EMEA's new "conditional" approval program will not negatively impact completion of confirmatory trials for products receiving U.S. accelerated approval, Office of Oncology Drug Products Director Richard Pazdur said

You may also be interested in...

Confirmatory Trial Early Planning Is Essential To Address Potential Problems

Sponsors should develop a strategy to address potential challenges to completion of accelerated approval confirmatory studies in advance of conducting the trials, members of FDA's Oncologic Drugs Advisory Committee suggested Nov. 8

“Exceptional” Approval Could Replace “Accelerated” For Rare Cancer Drugs

An "exceptional" approval process should be carved out of the accelerated approval program for products targeting rare cancers where there is little likelihood of completing confirmatory trials, members of FDA's Oncologic Drugs Advisory Committee recommended

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts